Nazione: Regno Unito
Lingua: inglese
Fonte: MHRA (Medicines & Healthcare Products Regulatory Agency)
Dabigatran etexilate mesilate
Boehringer Ingelheim Ltd
B01AE07
Dabigatran etexilate mesilate
150mg
Capsule
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: ; GTIN: 5012816096066
WHAT IS IN THIS LEAFLET 1. What Pradaxa is and what it is used for 2. What you need to know before you take Pradaxa 3. How to take Pradaxa 4. Possible side effects 5. How to store Pradaxa 6. Contents of the pack and other information 1. WHAT PRADAXA IS AND WHAT IT IS USED FOR Pradaxa contains the active substance dabigatran etexilate and belongs to a group of medicines called anticoagulants. It works by blocking a substance in the body which is involved in blood clot formation. Pradaxa is used in adults to: ‑ prevent blood clots in the brain (stroke) and other blood vessels in the body if you have a form of irregular heart rhythm called nonvalvular atrial fibrillation and at least one additional risk factor. ‑ treat blood clots in the veins of your legs and lungs and to prevent blood clots from re‑occurring in the vein of your legs and lungs. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE PRADAXA DO NOT TAKE PRADAXA ‑ if you are allergic to dabigatran etexilate or any of the other ingredients of this medicine (listed in section 6). ‑ if you have severely reduced kidney function. ‑ if you are currently bleeding. ‑ if you have a disease in an organ of the body that increases the risk of serious bleeding (e.g. stomach ulcer, injury or bleeding in the brain, recent surgery of the brain or eyes). ‑ if you have an increased tendency to bleed. This may be inborn, of unknown cause or due to other medicines. ‑ if you are taking medicines to prevent blood clotting (e.g. warfarin, rivaroxaban, apixaban or heparin), except when changing anticoagulant treatment or while having a venous or arterial line and you get heparin through this line to keep it open. ‑ if you have a severely reduced liver function or liver disease which could possibly cause death. ‑ if you are taking oral ketoconazole or itraconazole, medicines to treat fungal infections. ‑ if you are taking oral cyclosporine, a medicine to prevent organ rejection after transplantation. ‑ if you are taking dronedarone, a medicine used to treat abnorm Leggi il documento completo
OBJECT 1 PRADAXA 150 MG HARD CAPSULES Summary of Product Characteristics Updated 01-Feb-2018 | Boehringer Ingelheim Limited 1. Name of the medicinal product Pradaxa 150 mg hard capsules 2. Qualitative and quantitative composition Each hard capsule contains 150 mg of dabigatran etexilate (as mesilate). For the full list of excipients, see section 6.1. 3. Pharmaceutical form Hard capsule. Capsules with light blue, opaque cap and white, opaque body of size 0 filled with yellowish pellets. The cap is imprinted with the Boehringer Ingelheim company symbol, the body with “R150”. 4. Clinical particulars 4.1 Therapeutic indications Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischemic attack (TIA); age ≥ 75 years; heart failure (NYHA Class ≥ II); diabetes mellitus; hypertension. Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults 4.2 Posology and method of administration Posology _PREVENTION OF STROKE AND SYSTEMIC EMBOLISM IN ADULT PATIENTS WITH NVAF WITH ONE OR MORE RISK FACTORS _ _(SPAF) _ _TREATMENT OF DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM (PE), AND PREVENTION OF RECURRENT _ _DVT, AND PE IN ADULTS (DVT/PE) _ The recommended doses of Pradaxa in the indications SPAF, DVT and PE are shown in table 1. TABLE 1: DOSE RECOMMENDATIONS FOR SPAF, DVT AND PE DOSE RECOMMENDATION Prevention of stroke and systemic embolism in adult patients with NVAF with one or more risk factors (SPAF) 300 mg Pradaxa taken as one 150 mg capsule twice daily Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT, and PE in adults (DVT/PE) 300 mg Pradaxa taken as one 150 mg capsule twice daily following treatment with a parenteral anticoagulant for at least 5 days _DOSE REDUCTION RECOMMENDED _ Patients aged ≥80 years daily dose of 220 mg Pradaxa taken as one 110 mg capsule twice daily Patients Leggi il documento completo